Cargando...
Safety of Intravenous Iron in Hemodialysis Patients
Among end-stage renal disease patients maintained by hemodialysis, anemia has been managed primarily through erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron. Following concerns about the cardiovascular safety of ESAs and changes in the reimbursement policies in Medicare’s ESRD pro...
Guardado en:
| Publicado en: | Hemodial Int |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5517096/ https://ncbi.nlm.nih.gov/pubmed/28370957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hdi.12558 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|